How BetaVet® works

Proven formula backed by science.

  • Controls pain and inflammation associated with equine arthritis
  • Proven equine formula with two active ingredients
    • Betamethasone sodium phosphate - 3.15 mg1; a highly soluble betamethasone ester with a rapid onset of action2
    • Betamethasone acetate - 2.85 mg1; a less soluble betamethasone ester with a prolonged action2
  • Time to peak plasma concentrations (Tmax) achieved in as little as 4.5 to 8 hours*

* Clinical significance of these results is unknown.

The Pivotal field study showed over 75% efficacy.1

  • BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) clinical success rate of 75.73% (n=87) compared to Saline (Control) clinical success rate of 52.52% (n=61)
  • Field efficacy study based on a negative control, randomized masked trial of 239 horses — BetaVet® n=114; Saline (Control) n=115
  • Clinical success defined as improvement in one lameness grade according to the AAEP lameness scoring system, Day 5 after treatment
BetaVet pivotal field study results

BetaVet® target animal safety (TAS) study.3

  • N=32 horses of various breeds and ages
  • Ages 2-18 years, 16 geldings/16 mares
  • Weighing 827-1219 lbs

A 3-week target animal safety (TAS) study was conducted to evaluate the safety of BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) in mature, healthy horses.

  • 4 treatment groups, n=8 horses per group
  • BetaVet® was administered as an IA injection (left middle carpal joint) at (0X)* 0, (1X) 0.0225, (2X) 0.045, and (4X) 0.09 mg/lb, for three treatments, five days apart

*Control horses (0X) were administered Saline at a volume equivalent to the 4X group

BetaVet target animal safety study
  • Measurements and Observations – Daily observation, adverse events, physical examinations, injection site observations, body weights, and clinical pathology. Gross necropsy and histopathology were performed post-mortem
  • Results – Injection site reactions were the most common observations in all treatment groups, with the 4X BetaVet® group having the highest overall incidence and severity of injection site reactions

Conclusion – Treatment with BetaVet® was associated with dose dependent injection site abnormalities (swelling, pain, and lameness). This study supported the FDA approval of BetaVet® when administered IA to horses in a maximum of 2 joints at one-time does of 9 mg per joint.

Learn about an intramuscular treatment
for joint disease.

BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension)
For Intra-articular (I.A.) use in Horses.
INDICATIONS: BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) is indicated for the control of pain and inflammation associated with osteoarthritis in horses.
CONTRAINDICATIONS: BetaVet® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis. WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted congenital anomalies. Before use of corticosteroids in pregnant animals, the possible benefits should be weighed against potential hazards. Human Warnings: Not for use in humans. Keep this and all medications out of the reach of children. PRECAUTIONS: Corticosteroids, including BetaVet®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked. Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs should be approached with caution. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids. ADVERSE REACTIONS: Adverse reactions reported during a field study of 239 horses of various breeds which had been administered either BetaVet® (n=119) or a saline control (n=120) at five percent (5%) and above were: acute joint effusion and/or local injection site swelling (within 2 days of injection), 15% BetaVet® and 13% saline control; increased lameness (within the first 5 days), 6.7% BetaVet® and 8.3% saline control; loose stool, 5.9% BetaVet® and 8.3% saline control; increased heat in joint, 2.5% BetaVet® and 5% saline control; and depression, 5.9% BetaVet® and 1.6% saline control.
SHAKE WELL IMMEDIATELY BEFORE USE. For additional safety information, please see full prescribing information.
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
1. BetaVet® Package Insert, Rev 1/19.
2. Trotter GW. Intra-articular corticosteroids. In: Mcllwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia, PA; W.B. Saunders, 1996;237-256.
3. Freedom of Information Summary, BetaVet® NADA 141-418.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

About Us Our Brands